Try our corporate solution for free!

Reported EBITDA of Mayne Pharma 2014-2021

Published by Statista Research Department, Apr 2, 2022
In 2021 the Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of Mayne Pharma amounted to 66.1 million Australian dollars. Mayne Pharma is an ASX listed pharmaceutical company specializing in drug delivery systems.

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of Mayne Pharma 2014 to 2021 (in million Australian dollars)

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics
  • Incl. source references
  • Available to download in PNG, PDF, XLS format
Single Account
$39 $59 per month *
in the first 12 months
View for free
33% off until Jun 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

© Statista 2022
Download
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Pharmaceutical industry in the Asia-Pacific region"

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Further Content: You might find this interesting as well

Statistics

Topics

Vaccine industry in ChinaCoronavirus COVID-19 in ChinaPharmaceutical industry in ChinaInsurance industry in ChinaAging population in China
Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.
Menu